February 2007 Oncology News International

News
Article

Cover Story

  • Pancreatic Ca Vaccine Extends Survival After Surgery

Focus on Lung Cancer

  • BB-10901 Compound Delivers Potent Agent to CD56+ Tumors
  • First-line Nab-paclitaxel Shows Efficacy in NSCLC Trials

Focus on Hematology

  • High Response Rate for Lenalidomide Plus Melphalan and Prednisone in Newly Diagnosed Multiple Myeloma Patients

Cancer Care & Economics

  • Billing Plans for Routine Care Essential When Patients Enroll in Clinical Trials
  • RHIOs Allow Exchange of Electronic Info

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content